The table below shows Barinthus Biotherapeutics plc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$3.37M
-$14.90M
-$11.82M
-$3.17M
-$6.58M
-$7.97M
Capital expenditure
$0.00
$5.00K
$308.00K
$2.51M
$1.09M
$392.00K
Investing cash flow
$55.00K
-$5.00K
-$308.00K
-$2.51M
-$1.09M
-$392.00K
Dividends paid
-
-
-
BRNS operating cash flow (10-K history)
Barinthus Biotherapeutics plc. reported operating cash flow of -$47.98M for fiscal year 2025. That is down 65.8% from -$28.94M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$11.03M (FY 2020) to -$47.98M. Figures come from the company's audited annual reports as filed with the SEC.